KR101247528B1 - Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법 - Google Patents

Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법 Download PDF

Info

Publication number
KR101247528B1
KR101247528B1 KR1020077004993A KR20077004993A KR101247528B1 KR 101247528 B1 KR101247528 B1 KR 101247528B1 KR 1020077004993 A KR1020077004993 A KR 1020077004993A KR 20077004993 A KR20077004993 A KR 20077004993A KR 101247528 B1 KR101247528 B1 KR 101247528B1
Authority
KR
South Korea
Prior art keywords
delete delete
formula
methyl
amino
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077004993A
Other languages
English (en)
Korean (ko)
Other versions
KR20070047816A (ko
Inventor
디완 쩡
루이즈 벨라디넬리
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20070047816A publication Critical patent/KR20070047816A/ko
Application granted granted Critical
Publication of KR101247528B1 publication Critical patent/KR101247528B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
KR1020077004993A 2004-09-01 2005-08-30 Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법 Expired - Lifetime KR101247528B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
US60/606,675 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
KR20070047816A KR20070047816A (ko) 2007-05-07
KR101247528B1 true KR101247528B1 (ko) 2013-04-15

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077004993A Expired - Lifetime KR101247528B1 (ko) 2004-09-01 2005-08-30 Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법

Country Status (21)

Country Link
US (1) US20060058322A1 (enExample)
EP (1) EP1789053B1 (enExample)
JP (2) JP4929173B2 (enExample)
KR (1) KR101247528B1 (enExample)
CN (1) CN101043889B (enExample)
AU (1) AU2005282860B2 (enExample)
CA (1) CA2578702A1 (enExample)
DK (1) DK1789053T3 (enExample)
ES (1) ES2387653T3 (enExample)
HR (1) HRP20120712T1 (enExample)
IL (1) IL181634A (enExample)
MX (1) MX2007002437A (enExample)
NO (1) NO20071718L (enExample)
NZ (1) NZ553487A (enExample)
PL (1) PL1789053T3 (enExample)
PT (1) PT1789053E (enExample)
RS (1) RS52455B (enExample)
RU (1) RU2385322C2 (enExample)
SI (1) SI1789053T1 (enExample)
WO (1) WO2006028810A2 (enExample)
ZA (1) ZA200701777B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2357969C2 (ru) 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
CA3093234A1 (en) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
US20230365564A1 (en) * 2020-09-04 2023-11-16 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229106A1 (en) 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
CA2400206A1 (en) * 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
RU2318824C2 (ru) * 2001-11-09 2008-03-10 Си Ви Терапьютикс, Инк. Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229106A1 (en) 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
NZ553487A (en) 2010-09-30
RU2007107605A (ru) 2008-09-10
DK1789053T3 (da) 2012-08-06
MX2007002437A (es) 2007-08-14
CA2578702A1 (en) 2006-03-16
HK1107261A1 (en) 2008-04-03
JP4929173B2 (ja) 2012-05-09
IL181634A0 (en) 2007-07-04
RS52455B (sr) 2013-02-28
ES2387653T3 (es) 2012-09-27
CN101043889B (zh) 2010-11-03
WO2006028810A2 (en) 2006-03-16
US20060058322A1 (en) 2006-03-16
EP1789053A2 (en) 2007-05-30
IL181634A (en) 2015-05-31
PT1789053E (pt) 2012-08-09
AU2005282860B2 (en) 2012-03-22
CN101043889A (zh) 2007-09-26
RU2385322C2 (ru) 2010-03-27
WO2006028810A3 (en) 2006-09-28
ZA200701777B (en) 2008-09-25
SI1789053T1 (sl) 2012-09-28
HRP20120712T1 (hr) 2012-10-31
NO20071718L (no) 2007-03-30
AU2005282860A1 (en) 2006-03-16
KR20070047816A (ko) 2007-05-07
PL1789053T3 (pl) 2012-12-31
JP2008511654A (ja) 2008-04-17
JP2011246492A (ja) 2011-12-08
EP1789053B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
JP2011246492A (ja) Ａ２ｂアデノシンレセプターアンタゴニストを使用する創傷治癒の方法
AU2007227021B2 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
KR100937620B1 (ko) Ａ２ｂ 아데노신 수용체 길항제
KR101140186B1 (ko) Ａ2ｂ 아데노신 수용체 안타고니스트
AU2005295654B2 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
HK1107261B (en) Method of wound healing using a2b adenosine receptor antagonists
AU2012261721A1 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
AU2011202523B2 (en) A2B adenosine receptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100624

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120529

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20121220

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130318

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130320

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130321

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160309

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160309

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170315

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170315

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180308

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180308

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190312

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190312

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20200311

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20200311

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210218

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220216

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20230216

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20240110

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20250106

Start annual number: 13

End annual number: 13